Hosted on MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback